Central Nervous System Nongerminomatous Germ Cell Tumor, Childhood Germinoma
Conditions
Brief summary
This phase II trial studies how well chemotherapy followed by radiation therapy work in treating younger patients with newly diagnosed central nervous system germ cell tumors that have not spread to other parts of the brain, spinal canal, or body (localized). Drugs used as chemotherapy, such as carboplatin, etoposide, and ifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x rays to kill tumor cells. Giving chemotherapy followed by radiation therapy may kill more tumor cells.
Detailed description
PRIMARY OBJECTIVES: I. To determine, as measured by the 3-year progression-free survival (PFS) rate and patterns of failure, whether dose and volume of irradiation can be safely reduced to 30.6 Gy whole ventricular-field irradiation (WVI) plus 23.4 Gy primary site boost instead of 36 Gy craniospinal irradiation (CSI) plus primary site boost in the subgroup of children and young adults (ages 3 to =\< 21 years) with localized nongerminomatous germ cell tumor (NGGCT) who have a magnetic resonance imaging (MRI) and tumor marker criteria (cerebrospinal fluid \[CSF\] and serum) for confirmed complete response (CR) or partial response (PR) to induction chemotherapy and negative serum and cerebrospinal fluid (CSF) tumor markers OR in patients who have less than a PR after induction chemotherapy with negative tumor markers who undergo a second-look surgery and are found to have only mature teratoma, residual scar or fibrosis and fit the definition of CR/PR after second-look surgery. II. To determine, as measured by the 3-year PFS rate and patterns of failure, whether simplified chemotherapy followed by dose-reduced radiation therapy is effective for treating children and young adults (ages 3 to =\< 21 years) with localized primary central nervous system (CNS) germinoma who present with serum and/or CSF human chorionic gonadotropin-beta (hCGbeta) =\< 50 mIU/mL. III. To prospectively evaluate and longitudinally model the cognitive, social, and behavioral functioning of children and young adults who are treated with reduced radiation dose and volume of irradiation in Stratum 1 (NGGCT) and with dose-reduced radiation therapy in Stratum 2 (germinoma) using the ALTE07C1 protocol. SECONDARY OBJECTIVES: I. To estimate the PFS and overall survival (OS) distributions of patients with NGGCT treated with 30.6 Gy WVI and involved-field radiation therapy (IFR) focal boost to 54 Gy. II. To estimate the PFS and OS distributions of localized germinoma patients who present with a) serum and/or CSF hCGbeta =\< 50 mIU/mL and b) serum and/or CSF hCGbeta \> 50 mIU/mL and =\< 100 mIU/mL. OUTLINE: STRATUM I (NGGCT): Patients receive induction therapy comprising carboplatin intravenously (IV) over 15-60 minutes on day 1 and etoposide IV over 60-120 minutes on days 1-3 of courses 1, 3, and 5. Patients also receive ifosfamide IV over 60 minutes and etoposide over 60-120 minutes on days 1-5 of courses 2, 4, and 6. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or PR undergo 3-dimensional conformal radiation therapy (3DRT) or intensity modulated radiation therapy (IMRT) once daily (QD) 5 days a week for 6 weeks. Patients with normalization of markers who fail to achieve CR or PR are strongly recommended to undergo second-look surgery. Patients who achieve CR or PR after second-look surgery undergo 3DRT or IMRT QD 5 days a week for 6 weeks. STRATUM II (GERMINOMA): Patients receive induction therapy comprising carboplatin IV over 15-60 minutes on day 1 and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with CR or continued CR (CCR) undergo 3DRT or IMRT QD 5 days a week for 4 weeks. Patients with normalization of markers who fail to achieve CR or PR are strongly recommended to undergo second-look surgery. Patients found to have fibrosis, scar, mature teratoma, or non-viable tumor undergo 3DRT or IMRT QD 5 days a week for 4 weeks. Patients with stable disease (SD) or PR with \> 0.5 cm (suprasellar) or \> 1 cm (pineal) but =\< 1.5 cm residual disease do not undergo second-look surgery and undergo 3DRT or IMRT QD 5 days a week for 4 weeks. After completion of study treatment, patients are followed up at 3, 6, and 9 months, every 4 months for 24 months, 30 months, 36 months, and then annually for up to 60 months.
Interventions
RADIATION3-Dimensional Conformal Radiation Therapy
Undergo 3D-CRT
DRUGCarboplatin
Given IV
DRUGEtoposide
Given IV
DRUGIfosfamide
Given IV
RADIATIONIntensity-Modulated Radiation Therapy
Undergo IMRT
Sponsors
National Cancer Institute (NCI)
Children's Oncology Group
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Years to 21 Years
Healthy volunteers
No
Inclusion criteria
* Patients must be newly diagnosed with localized primary CNS NGGCT (Stratum 1) or localized primary CNS germinoma (Stratum 2); germ cell tumors located in the suprasellar, pineal, bifocal (pineal + suprasellar) and ventricles are eligible; tumors present in the above mentioned locations and with unifocal parenchymal extension are eligible * Stratum 1(NGGCT): Patients must have one of the following criteria: * Patients with serum and/or CSF hCGbeta \> 100 mIU/mL or any elevation of serum and/or CSF alpha-fetoprotein (AFP) \> 10 ng/mL or greater than the institutional normal are eligible, irrespective of biopsy results * Patients with any of the following elements on biopsy/resection are eligible, irrespective of serum and/or CSF hCGbeta and AFP levels: endodermal sinus tumor (yolk sac), embryonal carcinoma, choriocarcinoma, malignant/immature teratoma, and mixed GCT with malignant GCT elements * Stratum 2 (Germinoma): Patients must have both serum and CSF markers obtained (unless obtaining CSF is medically contraindicated) and must have one of the following criteria to be eligible: * Patients with institutional normal AFP (or =\< 10 ng/mL if no institutional normal exists) in both serum and CSF (unless medically contraindicated) AND hCGbeta 5 to =\< 50 mIU/mL in serum and/or CSF (unless medically contraindicated) (only 1 is required to be elevated) are eligible; no histologic confirmation required * Patients with bifocal (pineal + suprasellar) involvement or pineal lesion with diabetes insipidus (D1) AND hCGbeta =\< 100 mIU/mL in serum and/or CSF AND institutional normal AFP (or =\< 10 ng/mL if no institutional normal exists) in both serum and CSF (unless medically contraindicated) are eligible; no histologic confirmation required * Patients with histologically confirmed germinoma or germinoma mixed with mature teratoma and hCGbeta =\< 100 mIU/mL in serum and/or CSF and institutional normal AFP (or =\< 10 ng/mL if no institutional normal exists) in both serum and CSF (unless medically contraindicated) are eligible * All patients must have a cranial MRI with and without gadolinium at diagnosis/prior to enrollment; if surgical resection is performed, patients must have pre-operative and post-operative cranial MRI with and without gadolinium; the post-operative brain MRI should be obtained within 72 hours of surgery; if patient has a biopsy only, post-operative cranial MRI is recommended but not required; all patients must have a spine MRI with gadolinium obtained at diagnosis/prior to enrollment; Note: if the spine study is performed for the first time after surgical resection or biopsy, it is recommended to be obtained with and without gadolinium * Lumbar CSF must be obtained prior to study enrollment unless medically contraindicated; if a patient undergoes surgery and lumbar CSF cannot be obtained at this time, then it should be performed at least 10 days following surgery before study enrollment; false positive cytology can occur within 10 days of surgery; Note: patients with positive CSF cytology obtained prior to 10 days after surgery may have cytology repeated to determine eligibility * Patients must have CSF tumor markers obtained prior to enrollment unless medically contraindicated; ventricular CSF obtained at the time of CSF diversion procedure (if performed) is acceptable for tumor markers but lumbar CSF is preferred; in case CSF diversion and biopsy/surgery are combined, CSF tumor markers should be collected first * Patients must be enrolled on ALTE07C1 prior to enrollment on ACNS1123; patients must be enrolled within 31 days of definitive diagnostic surgery (day 0) or clinical diagnosis * Peripheral absolute neutrophil count (ANC) \>= 1,000/uL * Platelet count \>= 100,000/uL (transfusion independent) * Hemoglobin \>= 8.0 g/dL (may receive red blood cell \[RBC\] transfusions) * Creatinine clearance or radioisotope glomular filtration rate (GFR) \>= 70 mL/min/1.73 m\^2 OR serum creatinine based on age/gender as follows: * 0.8 mg/dL (2 to \< 6 years of age) * 1.0 mg/dL (6 to \< 10 years of age) * 1.2 mg/dL (10 to \< 13 years of age) * 1.5 mg/dL (male) and 1.4 mg/dL (female) (13 to \< 16 years of age) * 1.7 mg/dL (male) and 1.4 mg/dL (female) (\>= 16 years of age) * Total bilirubin =\< 1.5 times upper limit of normal (ULN) for age * Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) \< 2.5 times ULN * Patients with seizure disorder may be enrolled if well controlled * Patients must not be in status, coma, or assisted ventilation prior to study enrollment
Exclusion criteria
* Patients with mature teratoma or completely resected immature teratoma with normal tumor markers are not eligible * Patients with tumors located outside the ventricles (basal ganglia, thalamus) are not eligible * Patients with metastatic disease by cranial or spinal MRI evaluation or CSF cytology (unless medically contraindicated) are not eligible * Patients must not have received any prior tumor-directed therapy other than surgical intervention and corticosteroids * Female patients who are pregnant are ineligible * Lactating females are not eligible unless they have agreed not to breastfeed their infants * Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained * Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation * All patients and/or their parents or legal guardians must sign a written informed consent * All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 3-year Progression-free Survival (PFS) Rate of Patients With Nongerminomatous Germ Cell Tumor (NGGCT) Who Were Treated With Reduced Dose Whole Ventricular-field Irradiation | 3 years | Binomial estimate of the 3-year PFS rate defined as Yes for patients who were followed up per protocol and were progression free at 3-years, and No for those who either experienced a progression or were lost to follow-up/withdrew from the trial within 3 years from enrollment. Progression was determined by MRI using the COG Guidelines for Measurement of Tumor Size (\>25% increase in 2D or \>40% in 3D of the product of perpendicular diameters of the target lesion) as well as by tumor marker assessments which were mandatory for this study. |
| 3-year PFS Rate of Patients With Localized CNS Germinoma Who Were Treated With Reduced Dose Radiation Therapy | 3 years | Binomial estimate of the 3-year PFS rate defined as Yes for patients who were followed up per protocol and were progression free at 3-years, and No for those who either experienced a progression or were lost to follow-up/withdrew from the trial within 3 years from initiation of treatment. Progression was determined by MRI using the COG Guidelines for Measurement of Tumor Size (\>25% increase in 2D or \>40% in 3D of the product of perpendicular diameters of the target lesion) as well as by tumor marker assessments which were mandatory for this study. |
| Neurocognitive Function Using the ALTE07C1 Protocol | Up to 5 years | Estimated scores for the cognitive functions of processing speed, attention/concentration, and estimated IQ were assessed using the age-appropriate version of the Wechsler Scales of Intelligence. The range for the Processing Speed Index (PSI) is 45 to 155, with a mean of 100 and a standard deviation of 15. Estimated IQ was estimated using 2 subtests from the Wechsler Scales of Intelligence to derive a standard score with a mean of 100 and standard deviation of 15 with a range of 45 to 158. Scores from the 2 subtests were summed and translated to a standard score using published procedures. Attention/concentration was measured by the Digit Span subtest score from the Wechsler Scales of Intelligence. Subset scores have a range of 1-19, with a mean of 10 and standard deviation of 3. Higher scores on all these measures indicate higher or better cognitive performance, lower scores indicate lower or worse cognitive functioning. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Estimation of the PFS Distribution of Patients With NGGCT Treated With Involved-field Radiation Therapy (IFR) | Up to 3 years | Kaplan Meier estimate of the 3-year PFS is provided. PFS is the time interval measured from enrollment until progression or death from any cause or until last follow-up for those who were event free at the time of analysis. Patients who were lost to follow-up or withdrew consent were censored in this analysis. Progression was determined by MRI using the COG Guidelines for Measurement of Tumor Size (\>25% increase in 2D or \>40% in 3D of the product of perpendicular diameters of the target lesion) as well as by tumor marker assessments which were mandatory for this study. |
| Estimation of the OS Distribution of Patients With Localized Germinoma Patients and CSF Serum hCGbeta of 50 mIU/mL or Less or CSF Serum hCGbeta Greater Than 50 mIU/mL and Less Than or Equal to 100 mIU/mL | Up to 3 years | Kaplan Meier estimate of the 3-year overall survival (OS) is provided for each group. OS is the time interval measured from enrollment until death from any cause or until last follow-up for those who were alive at the time of analysis. Patients who were lost to follow-up or withdrew consent were censored in this analysis. |
| Estimation of the Overall Survival (OS) Distribution of Patients With NGGCT Treated With IFR Assessed | Up to 3 years | Kaplan Meier estimate of the 3-year overall survival (OS) is provided. OS is the time interval measured from enrollment until death from any cause or until last follow-up for those who were alive at the time of analysis. Patients who were lost to follow-up or withdrew consent were censored in this analysis. |
| Estimation of the PFS Distribution of Patients With Localized Germinoma Patients and Cerebrospinal Fluid (CSF) Serum hCGbeta of 50 mIU/mL or Less or CSF Serum hCGbeta Greater Than 50 mIU/mL and Less Than or Equal to 100 mIU/mL | Up to 3 years | Kaplan Meier estimate of the 3-year PFS rate is provided. PFS is the time interval measured from initiation of treatment until progression or death from any cause or until last follow-up for those who were event free at the time of analysis. Patients who were lost to follow-up or withdrew consent were censored in this analysis. Progression was determined by MRI using the COG Guidelines for Measurement of Tumor Size (\>25% increase in 2D or \>40% in 3D of the product of perpendicular diameters of the target lesion) as well as by tumor marker assessments which were mandatory for this study. |
Countries
Australia, Canada, New Zealand, Puerto Rico, United States
Participant flow
Recruitment details
Patients enrolled on the study from 6/27/2012 to 11/1/2016 on Stratum 1 and from 6/27/2012 to 10/26/2018 on Stratum 2
Pre-assignment details
There were 111 patients enrolled in Stratum 1 with localized nongerminomatous germ cell tumors (NGGCT) and 151 patients enrolled in Stratum 2 with localized CNS Germinoma (Germinoma). Of these 107 in Stratum 1 and 137 in Stratum 2 were deemed eligible for the study. This report is limited to eligible subjects.
Participants by arm
| Arm | Count |
|---|---|
| Stratum 1 Localized Non-Germinomatous Germ Cell Tumors (NGGCT) Patients receive induction therapy comprising carboplatin intravenously (IV) over 15-60 minutes on day 1 and etoposide IV over 60-120 minutes on days 1-3 of courses 1, 3, and 5. Patients also receive ifosfamide IV over 60 minutes and etoposide over 60-120 minutes on days 1-5 of courses 2, 4, and 6. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or PR undergo 3-dimensional conformal radiation therapy (3DRT) or intensity modulated radiation therapy (IMRT) once daily (QD) 5 days a week for 6 weeks. Patients with normalization of markers who fail to achieve CR or PR are strongly recommended to undergo second-look surgery. Patients who achieve CR or PR after second-look surgery undergo 3DRT or IMRT QD 5 days a week for 6 weeks. | 107 |
| Stratum 2 Localized Germinoma Patients receive induction therapy comprising carboplatin IV over 15-60 minutes on day 1 and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with CR or continued CR (CCR) undergo 3DRT or IMRT QD 5 days a week for 4 weeks. Patients with normalization of markers who fail to achieve CR or PR are strongly recommended to undergo second-look surgery. Patients found to have fibrosis, scar, mature teratoma, or non-viable tumor undergo 3DRT or IMRT QD 5 days a week for 4 weeks. Patients with stable disease (SD) or PR with \> 0.5 cm (suprasellar) or \> 1 cm (pineal) but =\< 1.5 cm residual disease do not undergo second-look surgery and undergo 3DRT or IMRT QD 5 days a week for 4 weeks. | 137 |
| Total | 244 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Induction Chemotherapy | Death | 2 | 1 |
| Induction Chemotherapy | Lack of Efficacy | 16 | 7 |
| Induction Chemotherapy | Physician Decision | 12 | 5 |
| Induction Chemotherapy | Radiotherapy can't be initiated in 6 wks | 2 | 3 |
| Induction Chemotherapy | Refusal of further protocol therapy | 5 | 6 |
| Induction Chemotherapy | Withdrawal by Subject | 0 | 2 |
| Radiation Therapy on Protocol | In-evaluable for reduced dose(18 Gy) | 0 | 14 |
| Radiation Therapy on Protocol | In-evaluable for reduced dose(30.6 Gy) | 4 | 0 |
| Radiation Therapy on Protocol | In-evaluable for RT dose (24Gy) | 0 | 9 |
| Radiation Therapy on Protocol | Lost to Follow-up | 4 | 5 |
| Radiation Therapy on Protocol | Withdrawal by Subject | 2 | 3 |
Baseline characteristics
| Characteristic | Stratum 1 Localized Non-Germinomatous Germ Cell Tumors (NGGCT) | Stratum 2 Localized Germinoma | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 100 Participants | 124 Participants | 224 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 7 Participants | 13 Participants | 20 Participants |
| Age, Continuous | 11.0 years | 14.1 years | 13.0 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 20 Participants | 16 Participants | 36 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 83 Participants | 113 Participants | 196 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 4 Participants | 8 Participants | 12 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 8 Participants | 14 Participants | 22 Participants |
| Race (NIH/OMB) Black or African American | 6 Participants | 9 Participants | 15 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants | 8 Participants | 9 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 14 Participants | 19 Participants | 33 Participants |
| Race (NIH/OMB) White | 78 Participants | 86 Participants | 164 Participants |
| Region of Enrollment Australia | 7 participants | 10 participants | 17 participants |
| Region of Enrollment Canada | 7 participants | 6 participants | 13 participants |
| Region of Enrollment New Zealand | 0 participants | 4 participants | 4 participants |
| Region of Enrollment United States | 93 participants | 117 participants | 210 participants |
| Sex: Female, Male Female | 27 Participants | 37 Participants | 64 Participants |
| Sex: Female, Male Male | 80 Participants | 100 Participants | 180 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 13 / 107 | 2 / 137 |
| other Total, other adverse events | 84 / 107 | 107 / 137 |
| serious Total, serious adverse events | 5 / 107 | 1 / 137 |
Outcome results
Primary
3-year PFS Rate of Patients With Localized CNS Germinoma Who Were Treated With Reduced Dose Radiation Therapy
Binomial estimate of the 3-year PFS rate defined as Yes for patients who were followed up per protocol and were progression free at 3-years, and No for those who either experienced a progression or were lost to follow-up/withdrew from the trial within 3 years from initiation of treatment. Progression was determined by MRI using the COG Guidelines for Measurement of Tumor Size (\>25% increase in 2D or \>40% in 3D of the product of perpendicular diameters of the target lesion) as well as by tumor marker assessments which were mandatory for this study.
Time frame: 3 years
Population: Localized CNS Germinoma treated with dose-reduced RT (18 Gy WVI + 12 Gy primary site boost) and had complete response (CR) after induction chemotherapy by MRI and tumor marker criteria; or underwent second-look surgery and were found to have mature teratoma, residual scar or fibrosis and fit the definition of CR after second-look surgery.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Stratum 1 Localized Non-Germinomatous Germ Cell Tumors (NGGCT) | 3-year PFS Rate of Patients With Localized CNS Germinoma Who Were Treated With Reduced Dose Radiation Therapy | 86.49 percentage of patients |
Primary
3-year Progression-free Survival (PFS) Rate of Patients With Nongerminomatous Germ Cell Tumor (NGGCT) Who Were Treated With Reduced Dose Whole Ventricular-field Irradiation
Binomial estimate of the 3-year PFS rate defined as Yes for patients who were followed up per protocol and were progression free at 3-years, and No for those who either experienced a progression or were lost to follow-up/withdrew from the trial within 3 years from enrollment. Progression was determined by MRI using the COG Guidelines for Measurement of Tumor Size (\>25% increase in 2D or \>40% in 3D of the product of perpendicular diameters of the target lesion) as well as by tumor marker assessments which were mandatory for this study.
Time frame: 3 years
Population: Localized NGGCT treated with 30.6 Gy WVF RT + 23.4 Gy primary site boost. Patients must have had complete response (CR) or partial response (PR) to induction chemotherapy by MRI and markers; or underwent second-look surgery and were found to have mature teratoma, residual scar or fibrosis and fit the definition of CR/PR after second-look surgery.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Stratum 1 Localized Non-Germinomatous Germ Cell Tumors (NGGCT) | 3-year Progression-free Survival (PFS) Rate of Patients With Nongerminomatous Germ Cell Tumor (NGGCT) Who Were Treated With Reduced Dose Whole Ventricular-field Irradiation | 83.33 percentage of patients |
Primary
Neurocognitive Function Using the ALTE07C1 Protocol
Estimated scores for the cognitive functions of processing speed, attention/concentration, and estimated IQ were assessed using the age-appropriate version of the Wechsler Scales of Intelligence. The range for the Processing Speed Index (PSI) is 45 to 155, with a mean of 100 and a standard deviation of 15. Estimated IQ was estimated using 2 subtests from the Wechsler Scales of Intelligence to derive a standard score with a mean of 100 and standard deviation of 15 with a range of 45 to 158. Scores from the 2 subtests were summed and translated to a standard score using published procedures. Attention/concentration was measured by the Digit Span subtest score from the Wechsler Scales of Intelligence. Subset scores have a range of 1-19, with a mean of 10 and standard deviation of 3. Higher scores on all these measures indicate higher or better cognitive performance, lower scores indicate lower or worse cognitive functioning.
Time frame: Up to 5 years
Population: All eligible patients who received the radiation therapy were included as evaluable patients for analysis.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Stratum 1 Localized Non-Germinomatous Germ Cell Tumors (NGGCT) | Neurocognitive Function Using the ALTE07C1 Protocol | Attention/Concentration at 30 months | 10.1 Standardized Scores |
| Stratum 1 Localized Non-Germinomatous Germ Cell Tumors (NGGCT) | Neurocognitive Function Using the ALTE07C1 Protocol | Estimated IQ at 60 months | 97.3 Standardized Scores |
| Stratum 1 Localized Non-Germinomatous Germ Cell Tumors (NGGCT) | Neurocognitive Function Using the ALTE07C1 Protocol | Estimated IQ at 9 months | 94.3 Standardized Scores |
| Stratum 1 Localized Non-Germinomatous Germ Cell Tumors (NGGCT) | Neurocognitive Function Using the ALTE07C1 Protocol | Processing Speed at 9 months | 90.1 Standardized Scores |
| Stratum 1 Localized Non-Germinomatous Germ Cell Tumors (NGGCT) | Neurocognitive Function Using the ALTE07C1 Protocol | Attention/Concentration at 60 months | 9.3 Standardized Scores |
| Stratum 1 Localized Non-Germinomatous Germ Cell Tumors (NGGCT) | Neurocognitive Function Using the ALTE07C1 Protocol | Processing Speed at 30 months | 93.4 Standardized Scores |
| Stratum 1 Localized Non-Germinomatous Germ Cell Tumors (NGGCT) | Neurocognitive Function Using the ALTE07C1 Protocol | Estimated IQ at 30 months | 101.3 Standardized Scores |
| Stratum 1 Localized Non-Germinomatous Germ Cell Tumors (NGGCT) | Neurocognitive Function Using the ALTE07C1 Protocol | Processing Speed at 60 months | 90.1 Standardized Scores |
| Stratum 1 Localized Non-Germinomatous Germ Cell Tumors (NGGCT) | Neurocognitive Function Using the ALTE07C1 Protocol | Attention/Concentration at 9 months | 9.4 Standardized Scores |
| Stratum 2 Localized Germinoma | Neurocognitive Function Using the ALTE07C1 Protocol | Processing Speed at 60 months | 97.5 Standardized Scores |
| Stratum 2 Localized Germinoma | Neurocognitive Function Using the ALTE07C1 Protocol | Attention/Concentration at 9 months | 10.0 Standardized Scores |
| Stratum 2 Localized Germinoma | Neurocognitive Function Using the ALTE07C1 Protocol | Attention/Concentration at 30 months | 9.8 Standardized Scores |
| Stratum 2 Localized Germinoma | Neurocognitive Function Using the ALTE07C1 Protocol | Attention/Concentration at 60 months | 10.2 Standardized Scores |
| Stratum 2 Localized Germinoma | Neurocognitive Function Using the ALTE07C1 Protocol | Estimated IQ at 9 months | 99.0 Standardized Scores |
| Stratum 2 Localized Germinoma | Neurocognitive Function Using the ALTE07C1 Protocol | Estimated IQ at 30 months | 102.9 Standardized Scores |
| Stratum 2 Localized Germinoma | Neurocognitive Function Using the ALTE07C1 Protocol | Estimated IQ at 60 months | 104.5 Standardized Scores |
| Stratum 2 Localized Germinoma | Neurocognitive Function Using the ALTE07C1 Protocol | Processing Speed at 9 months | 91.8 Standardized Scores |
| Stratum 2 Localized Germinoma | Neurocognitive Function Using the ALTE07C1 Protocol | Processing Speed at 30 months | 95.6 Standardized Scores |
Secondary
Estimation of the OS Distribution of Patients With Localized Germinoma Patients and CSF Serum hCGbeta of 50 mIU/mL or Less or CSF Serum hCGbeta Greater Than 50 mIU/mL and Less Than or Equal to 100 mIU/mL
Kaplan Meier estimate of the 3-year overall survival (OS) is provided for each group. OS is the time interval measured from enrollment until death from any cause or until last follow-up for those who were alive at the time of analysis. Patients who were lost to follow-up or withdrew consent were censored in this analysis.
Time frame: Up to 3 years
Population: The eligible patients with localized germinoma and CSF serum hCGbeta of 50 mIU/mL or less or CSF serum hCGbeta greater than 50 mIU/mL and less than or equal to 100 mIU/mL
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Stratum 1 Localized Non-Germinomatous Germ Cell Tumors (NGGCT) | Estimation of the OS Distribution of Patients With Localized Germinoma Patients and CSF Serum hCGbeta of 50 mIU/mL or Less or CSF Serum hCGbeta Greater Than 50 mIU/mL and Less Than or Equal to 100 mIU/mL | 98.38 percentage of patients |
| Stratum 2 Localized Germinoma | Estimation of the OS Distribution of Patients With Localized Germinoma Patients and CSF Serum hCGbeta of 50 mIU/mL or Less or CSF Serum hCGbeta Greater Than 50 mIU/mL and Less Than or Equal to 100 mIU/mL | 100 percentage of patients |
Secondary
Estimation of the Overall Survival (OS) Distribution of Patients With NGGCT Treated With IFR Assessed
Kaplan Meier estimate of the 3-year overall survival (OS) is provided. OS is the time interval measured from enrollment until death from any cause or until last follow-up for those who were alive at the time of analysis. Patients who were lost to follow-up or withdrew consent were censored in this analysis.
Time frame: Up to 3 years
Population: Localized NGGCT treated with 30.6 Gy WVF RT + 23.4 Gy primary site boost. Patients must have had complete response (CR) or partial response (PR) to induction chemotherapy by MRI and markers; or underwent second-look surgery and were found to have mature teratoma, residual scar or fibrosis and fit the definition of CR/PR after second-look surgery.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Stratum 1 Localized Non-Germinomatous Germ Cell Tumors (NGGCT) | Estimation of the Overall Survival (OS) Distribution of Patients With NGGCT Treated With IFR Assessed | 92.42 percentage of patients |
Secondary
Estimation of the PFS Distribution of Patients With Localized Germinoma Patients and Cerebrospinal Fluid (CSF) Serum hCGbeta of 50 mIU/mL or Less or CSF Serum hCGbeta Greater Than 50 mIU/mL and Less Than or Equal to 100 mIU/mL
Kaplan Meier estimate of the 3-year PFS rate is provided. PFS is the time interval measured from initiation of treatment until progression or death from any cause or until last follow-up for those who were event free at the time of analysis. Patients who were lost to follow-up or withdrew consent were censored in this analysis. Progression was determined by MRI using the COG Guidelines for Measurement of Tumor Size (\>25% increase in 2D or \>40% in 3D of the product of perpendicular diameters of the target lesion) as well as by tumor marker assessments which were mandatory for this study.
Time frame: Up to 3 years
Population: The eligible patients with localized germinoma and CSF serum hCGbeta of 50 mIU/mL or less or CSF serum hCGbeta greater than 50 mIU/mL and less than or equal to 100 mIU/mL.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Stratum 1 Localized Non-Germinomatous Germ Cell Tumors (NGGCT) | Estimation of the PFS Distribution of Patients With Localized Germinoma Patients and Cerebrospinal Fluid (CSF) Serum hCGbeta of 50 mIU/mL or Less or CSF Serum hCGbeta Greater Than 50 mIU/mL and Less Than or Equal to 100 mIU/mL | 93.26 percentage of patients |
| Stratum 2 Localized Germinoma | Estimation of the PFS Distribution of Patients With Localized Germinoma Patients and Cerebrospinal Fluid (CSF) Serum hCGbeta of 50 mIU/mL or Less or CSF Serum hCGbeta Greater Than 50 mIU/mL and Less Than or Equal to 100 mIU/mL | 80.00 percentage of patients |
Secondary
Estimation of the PFS Distribution of Patients With NGGCT Treated With Involved-field Radiation Therapy (IFR)
Kaplan Meier estimate of the 3-year PFS is provided. PFS is the time interval measured from enrollment until progression or death from any cause or until last follow-up for those who were event free at the time of analysis. Patients who were lost to follow-up or withdrew consent were censored in this analysis. Progression was determined by MRI using the COG Guidelines for Measurement of Tumor Size (\>25% increase in 2D or \>40% in 3D of the product of perpendicular diameters of the target lesion) as well as by tumor marker assessments which were mandatory for this study.
Time frame: Up to 3 years
Population: Localized NGGCT treated with 30.6 Gy WVF RT + 23.4 Gy primary site boost. Patients must have had complete response (CR) or partial response (PR) to induction chemotherapy by MRI and markers; or underwent second-look surgery and were found to have mature teratoma, residual scar or fibrosis and fit the definition of CR/PR after second-look surgery.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Stratum 1 Localized Non-Germinomatous Germ Cell Tumors (NGGCT) | Estimation of the PFS Distribution of Patients With NGGCT Treated With Involved-field Radiation Therapy (IFR) | 87.88 percentage of patients |